Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification

International Journal of Obesity

Volumn 27, Issue 12, 2003, Pages 1486-1493

  Carlos Poston, W S ^a   Reeves, R S ^b   Haddock, C K ^a   Stormer, S ^b   Balasubramanyam, A ^b   Satterwhite, O ^b   Taylor, J E ^a   Foreyt, J P ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Culturally appropriate; Mexican American; Orlistat; Women

Indexed keywords

TETRAHYDROLIPSTATIN;

ADULT; ANALYSIS OF VARIANCE; ANTHROPOMETRIC PARAMETERS; ARTICLE; BEHAVIOR MODIFICATION; BEHAVIOR THERAPY; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CULTURAL FACTOR; FATTY STOOL; FECES URGENCY; FEMALE; FLATULENCE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HISPANIC; HUMAN; INCREASED DEFECATION; LIFESTYLE; LOW FAT DIET; OBESITY; OILY STOOL; OPEN STUDY; OUTCOMES RESEARCH; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

ADULT; AGED; ANTI-OBESITY AGENTS; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LACTONES; LIFE STYLE; LIPASE; MEXICAN AMERICANS; MIDDLE AGED; OBESITY; RISK FACTORS; TREATMENT OUTCOME; TREATMENT REFUSAL; WEIGHT LOSS;

PROTEUS ANGUINUS;

EID: 0348141021     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802439     Document Type: Article

References (40)

1. National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity: the evidence report. US Government Press: Washington, DC; 1998.
2. Samet JM, Coultas DB, Howard CA, Skipper CA, Hanis CL. Diabetes, gallbladder disease, obesity, and hypertension among Hispanics in New Mexico. Am J Epidemiol 1988; 128: 1302-1311.
3. Stern MP, Rosenthal M, Haffner SM, Hazuda HP, Franco LJ. Sex differences on the effects of sociocultural status on diabetes and cardiovascular risk factors in Mexican Americans: the San Antonio Heart Study. Am J Epidemiol 1984; 120: 834-851.
4. Mueller WH, Joos SK, Hanis CL, Zavalewta AN, Eichner J, Schull WJ. The Diabetes Alert Study: growth, fatness, and fat patterning, adolescence through adulthood in Mexican Americans. Am J Phys Anthropol 1984; 64: 389-399.
5. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288: 1723-1727.
6. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
7. Haffner SM, Stern MP, Hazuda HP, Rosenthal M, Knapp JA, Malinia RM. Role of obesity and fat distribution in non-insulin dependent diabetes mellitus in Mexican Americans and non-hispanic whites. Diabetes Care 1986; 9: 153-161.
8. Reichley KB, Mueller WH, Hanis CL, Joos SK, Tulloch BR, Barton S, Schull WJ. Centralized obesity and cardiovascular disease risk in Mexican Americans. Am J Epidemiol 1987; 125: 373-386.
9. Joos SK, Mueller WH, Hanis CL, Schull WJ. Diabetes alert study: weight history and upper body obesity in diabetic and non-diabetic Mexican American adults. Ann Hum Biol 1984; 11: 167.
10. Hanis CL, Ferrell RE, Barton SA, Aguilar L, Garza-Ibarra A, Tulloch BR, Garcia CA, Schull WJ. Diabetes among Mexican Americans in Starr County, Texas. Am J Epidemiol 1983; 118: 659-672.
11. Lean MEJ, Powrie JK, Anderson AS, Garwaithe PH. Obesity, weight loss, and prognosis in type 2 diabetes. Diabet Med 1990; 7: 228-233.
12. Oberman A, Wassertheil-Smoller S, Langford HG, Blaufox MD, Davis BR, Blaszkowski T, Zimbaldi N, Hawkins CM. Pharmacologic and nutritional treatment of mild hypertension: changes in cardiovascular risk status. Ann Intern Med 1990; 112: 89-95.
13. Watts NB, Spanheimer RG, DiGirolamo M, Gebhart SS, Musey VC, Siddiq YK, Phillips LS. Prediction of glucose response to weight loss in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1990; 150: 803-806.
14. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147: 1749-1753.
15. Foreyt JP. Weight loss in minority populations. In: Fairburn CG, Brownell KD (eds). Eating disorders and obesity: a comprehensive handbook, 2nd edn. The Guilford Press: New York; 2002. pp 583-587.
16. Kumanyika SK, Obarzanek E, Stevens VJ, Hebert PR, Whelton PK. Weight-loss experience of black and white participants in NHLBI-sponsored clinical trials. Am J Clin Nutr 1991; 53: 1631S-1638S.
17. Kumanyika SK, Espeland MA, Bahnson JL, Bottom JB, Charleston JB, Folmar S, Wilson AC, Whelton PK. Ethnic comparison of weight loss in the trial of nonpharmacologic interventions in the elderly. Obes Res 2002; 10: 96-106.
18. Cousins JH, Rubovits DS, Dunn JK, Reeves RS, Ramirez AG, Foreyt JP. Family versus individually oriented intervention for weight loss in Mexican American women. Public Health Rep 1992; 107: 549-555.
19. Poston II WS, Haddock CK, Olvera NE, Suminski RR, Reeves RS, Dunn JK, Hanis CL, Foreyt JP. Evaluation of a culturally appropriate intervention to increase physical activity. Am J Health Behav 2001; 25: 396-406.
20. Wing RR, Anglin K. Effectiveness of a behavioral weight control program for Blacks and Whites with NIDDM. Diab Care 1996; 19: 409-413.
21. Wylie-Rosset J, Wassertheil-Smoller S, Blaufox MD, Davis BR, Langford HG, Oberman A, Jennings S, Hataway H, Stern J, Zimbaldi N. Trial of antihypertensive intervention and management: greater efficacy with weight reduction than with a sodium-potassium intervention. J Am Diet Assoc 1993; 93: 408-415.
22. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD. Efficacy and safety of sibutramine in obese White and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160: 2185-2191.
23. Martinez-Cuellar GE, Ruiz AM, Monsalve MCR, Berber A. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res 2000; 8: 71-82.
24. Poston WSC, Haddock CK, Dill PL, Thayer B, Foreyt JP. Lifestyle treatments in randomized clinical trials of pharmacotherapies for obesity: data from 40 years of research. Obes Res 2001; 9: 552-563.
25. Foreyt JP, Ramirez AG, Cousins JH. Cuidando El Corazon - a weight reduction intervention for Mexican American women. Am J Clin Nutr 1991; 53: 1639S-1641S.
26. Poston WSC, Foreyt JP. Successful management of the obese patient. Am Fam Physician 2000; 61: 3615-3622.
27. Pate RR, Prat M, Blair SN, Haskell WL, Macera CA, Bouchard C, Buchner D, Ettinger W, Heath GW, King AC, Kriska A, Leon AS, Marcus BH, Morris J, Paffenbarger RS, Patrick K, Pollock ML, Rippe JM, Sallis J, Wilmore JH. Physical activity and health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995; 273: 402-407.
28. Dunn AL, Marcus BH, Kampert JB, Garcia ME, Kohl HW, Blair SN. Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness: a randomized trial. JAMA 1999; 281: 327-334.
29. National Institutes of Health (NIH)/National Heart, Lung, Blood Institute (NHLBI). The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH Publication No. 98-4080. US Government Press: Washington, DC; 1997.
30. Boudes P. Drug compliance in therapeutic trials - a review. Control Clin Trials 1998; 19: 257-268.
31. Burke LE, Dunbar-Jacobs J. Adherence to medication, diet, and activity recommendations: from assessment to maintenance. J Cardiovasc Nurs 1995; 9: 62-79.
32. Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action. Circulation 1997; 95: 1085-1090.
33. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials: the CONSORT Statement. JAMA 1996; 276: 637-639.
34. Haddock CK, Poston WSC, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002; 26: 262-273.
35. Finer N, James WPT, Kopelman PG, Lean MEJ, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000; 24: 306-313.
36. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-242.
37. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF. Effect of sibutramine on weight maintenance after weight loss: a randomised trial Lancet 2000; 356: 2119-2125.
38. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight gain in obese patients. Lancet 1998; 352: 167-173.
39. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998; 22: 39-47.
40. Sjöström L, Torgerson JS, Hauptman J, Boldrin M. XENDOS (XENical in the prevention of diabetes in Obese Subjects): a landmark study. Presented at 9th International Congress on Obesity, August 24-29, 2002, São Paulo, Brasil.